Patent · US Active

Marker for gastrointestinal tumors

US11442065B2 · kind B2 · utility

0Cited by

1References

5Claims

0Family size

Assignee

Rhode Island Hospital · US

Inventors

Wentian Yang · Central Falls, US
Lijun Wang · Lo Wu, CN
Douglas Moore · Barrington, US

Key dates

Filing date	Mar 30, 2020
Grant date	Sep 13, 2022
Priority date	—
Expiry date	Sep 27, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.